Clinical Trial Update: Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM [Phase 3]

View source ↗

Summary

This update reports the efficacy results from a Phase 3 trial of Symbicort pMDI administered once daily in adolescents and adults with asthma over 12 weeks; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Symbicort (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: COMPLETED